Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Symptoms and General Pathology

Digestive System Diseases

Respiratory Tract (Lung and Bronchial) Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Breast Neoplasms

Neoplasm Metastasis

Stomach Neoplasms

Lung Neoplasms

Recurrence

Carcinoma, Renal Cell

Liver Neoplasms

Skin Neoplasms

Kidney Neoplasms

Neoplasm Recurrence, Local

Neoplasms, Second Primary

Neoplastic Processes

Disease Attributes

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Stomach Cancer

Esophageal Cancer

Renal Cell Carcinoma

Hematinics

All Drugs and Chemicals

Anti-Infective Agents

Antineoplastic Agents

Liver Extracts

Poly I-C

Antiviral Agents

Interferons

Immunologic Factors

NS-9 [Poly I: Poly C]

This study is to investigate the safety of NS-9 and to see how well it is tolerated in patients with cancer that has metastasized (spread) to the liver from another primary tumor. NS-9 is a drug developed to go to the liver to cause cell death specifically in tumor cells. This study is also set up to determine the best dose to use.

This study requires subjects to undergo 2 treatment cycles of NS-9. Each cycle consists of once daily, 1-hour I.V. infusions of the drug for 5 days followed by a 23-day rest period. During the rest period, subjects are seen at the clinic once weekly for evaluation. Subjects having favorable or stable results after 2 cycles may continue to receive NS-9 in the extension phase of the study until the disease progresses or until they get a side effect that prevents them from continuing with therapy.

After each two cycles, if appropriate, the liver tumor will be measured by radiologic imaging to compare it to its pre-treatment size.

Study of NS-9 in Patients With Liver Metastases

A Phase I, Open-Label, Dose Escalation Study of Intravenously Administered NS-9 in Subjects With Liver Metastases From Various Primary Cancers

NS Pharma, Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Study of NS-9 in Patients With Liver Metastases	NCT00094003	Liver Neoplasms Neoplasm Metast... Local Neoplasm ...	NS-9 [Poly I: P...	18 Years -	NS Pharma, Inc.
Study of NS-9 in Patients With Liver Metastases	NCT00094003	Liver Neoplasms Neoplasm Metast... Local Neoplasm ...	NS-9 [Poly I: P...	18 Years -	NS Pharma, Inc.

Spots Global Cancer Trial Database for local neoplasm recurrences